Forward Pharma A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FWPAY research report →
Companywww.forward-pharma.com
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
- CEO
- Claus Bo Søndergaard Svendsen
- IPO
- 2014
- Employees
- 4
- HQ
- Copenhagen, DK
Price Chart
Valuation
- Market Cap
- $7.45M
- P/E
- 2118.18
- P/S
- 0.00
- P/B
- 2.69
- EV/EBITDA
- 37.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- 2060.64%
- Net Margin
- -47.87%
- ROE
- 0.12%
- ROIC
- 0.26%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,892,000 · 70.66%
- EPS
- $-77.41 · 71.19%
- Op Income
- $-3,874,000
- FCF YoY
- 58.71%
Performance & Tape
- 52W High
- $882.86
- 52W Low
- $200.00
- 50D MA
- $417.99
- 200D MA
- $548.55
- Beta
- 1.02
- Avg Volume
- 11
Get TickerSpark's AI analysis on FWPAY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FWPAY Coverage
We haven't published any research on FWPAY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FWPAY Report →